Filter Results:
(309)
Show Results For
- All HBS Web
(402)
- News (48)
- Research (309)
- Multimedia (1)
- Faculty Publications (248)
Show Results For
- All HBS Web
(402)
- News (48)
- Research (309)
- Multimedia (1)
- Faculty Publications (248)
Sort by
- June 2015
- Supplement
MINTing Innovation at NewYork-Presbyterian (B)
By: Richard G. Hamermesh and Michael Norris
This short (B) case gives an update on the progress that MINT has made at NYP since the end of the (A) case. View Details
Hamermesh, Richard G., and Michael Norris. "MINTing Innovation at NewYork-Presbyterian (B)." Harvard Business School Supplement 815-113, June 2015.
- March 2015
- Case
Bloodbuy
By: Richard G. Hamermesh and Michael Norris
In 2015, Chris Godfrey, founder and CEO of Bloodbuy, has to consider the best path to growth for his young company, which is attempting to disrupt the blood donation industry. View Details
Keywords: Health Care; Health Care Entrepreneurship; Blood Donation; Health Care and Treatment; Entrepreneurship; Health Industry; United States
Hamermesh, Richard G., and Michael Norris. "Bloodbuy." Harvard Business School Case 815-114, March 2015.
- July 2012 (Revised May 2024)
- Case
Lyric Dinner Theater (A)
By: Richard G. Hamermesh and Jim Sharpe
Looking back at five years of losses, Rivka Belzer, a newly minted MBA, steps into her family owned business with their mandate to turn it around or close it. In her first six months, she has made a number of changes, with mixed results, but is beginning to show a... View Details
Keywords: Entrepreneurs; Entrepreneurial Management; Crisis Management; Family Business; Turnarounds; Financial Crisis; Boards Of Directors; Operations Management; Strategy Implementation; Career Planning; Entrepreneurship; Entertainment and Recreation Industry; United States
Hamermesh, Richard G., and Jim Sharpe. "Lyric Dinner Theater (A)." Harvard Business School Case 813-043, July 2012. (Revised May 2024.)
- December 2008 (Revised October 2013)
- Case
Amylin Pharmaceuticals: Diabetes and Beyond (A)
By: Richard G. Hamermesh and Rachel Gordon
Ginger Graham, CEO of Amylin Pharmaceuticals, joined the company with the expectation of taking the company's signature drug, Symlin, to market. However, unforeseen regulatory challenges have put the approval process in jeopardy. At the same time, the company has a... View Details
Keywords: Regulations; Drug Regulations; Symlin; Negotiation; Governing Rules, Regulations, and Reforms; Resource Allocation; Negotiation Deal; Product Development; Research and Development; Commercialization; Pharmaceutical Industry; United States
Hamermesh, Richard G., and Rachel Gordon. "Amylin Pharmaceuticals: Diabetes and Beyond (A)." Harvard Business School Case 809-011, December 2008. (Revised October 2013.)
- September 2007 (Revised May 2009)
- Case
Syndexa and Technology Transfer at Harvard University
By: Richard G. Hamermesh and David Kiron
Gokhan Hotamisligil is a star researcher at Harvard School of Public Health who has made groundbreaking discoveries linking fat cells, inflammation, and diabetes. He now wants to form a company to commercialize these discoveries. At the same time, Isaac Kohlberg, the... View Details
Keywords: Business Startups; Higher Education; Entrepreneurship; Innovation and Invention; Intellectual Property; Rights; Agreements and Arrangements; Science-Based Business; Commercialization; Biotechnology Industry; Health Industry
Hamermesh, Richard G., and David Kiron. "Syndexa and Technology Transfer at Harvard University." Harvard Business School Case 808-073, September 2007. (Revised May 2009.)
- March 2006
- Teaching Note
Cutlass Capital, L.P. (TN)
By: Richard G. Hamermesh and Erin Seefeld
Teaching Note to 805075. View Details
Keywords: Financial Services Industry
- March 2006
- Teaching Note
Fred Khosravi and AccessClosure (TN)
By: Richard G. Hamermesh and Erin Seefeld
Teaching Note to (806-044). View Details
- January 2006 (Revised May 2007)
- Case
Endo Pharmaceuticals (A): From LBO to...?
By: Richard G. Hamermesh and Brian DeLacey
Endo Pharmaceuticals was formed in 1997 as a leveraged buyout spin-off from DuPont Merck. In 1999, it must decide whether to do an IPO or merge with a smaller company. View Details
Keywords: Private Equity; Initial Public Offering; Leveraged Buyouts; Mergers and Acquisitions; Health Care and Treatment; Pharmaceutical Industry; United States
Hamermesh, Richard G., and Brian DeLacey. "Endo Pharmaceuticals (A): From LBO to...?" Harvard Business School Case 806-064, January 2006. (Revised May 2007.)
- January 2002 (Revised July 2002)
- Teaching Note
Vialog Corporation (TN)
By: Richard G. Hamermesh and Michele Lutz
- January 2001 (Revised April 2001)
- Case
Lawyers & Leases
By: Richard G. Hamermesh and Michele Lutz
Profiles Rajath Chaundry, an aspiring entrepreneur, as he attempts to secure office space for his growing team, select a lawyer, and continue to build his fledgling enterprise, eLearning.com. Designed to be used in an entrepreneurial management or small business course... View Details
Keywords: Entrepreneurship; Business or Company Management; Business Ventures; Corporate Entrepreneurship; Intellectual Property; Management Succession; Leasing; Negotiation; Education Industry; Legal Services Industry
Hamermesh, Richard G., and Michele Lutz. "Lawyers & Leases." Harvard Business School Case 801-166, January 2001. (Revised April 2001.)
- December 1998 (Revised May 1999)
- Case
Specialty Medical Chemicals
By: Richard G. Hamermesh and Lucinda Doran
A new general manager is supposed to rekindle growth. Seven months later, he questions the abilities of his direct reports. An organizational psychologist is brought in to assess his people. The general manager now has to decide who to keep and how to structure his... View Details
Keywords: Decisions; Employees; Leadership Development; Management Teams; Organizational Structure; Cognition and Thinking
Hamermesh, Richard G., and Lucinda Doran. "Specialty Medical Chemicals." Harvard Business School Case 399-094, December 1998. (Revised May 1999.)
- August 2013 (Revised October 2013)
- Case
MedImmune Ventures
By: Richard G. Hamermesh and David Lane
Ron Laufer is the new Senior Managing Director of MedImmune Ventures, the corporate venture capital arm of AstraZeneca, a leading pharmaceuticals firm. Laufer has to decide whether to pursue a high-potential, but very risky, early-stage investment. The decision Laufer... View Details
Keywords: MedImmune; MedImmune Ventures; AstraZeneca; NeuProtect; Corporate Venturing; Biotechnology; Venture Investing; Venture Capital; Health Care and Treatment; Pharmaceutical Industry; Financial Services Industry; Biotechnology Industry; United States; Australia; Europe; London
Hamermesh, Richard G., and David Lane. "MedImmune Ventures." Harvard Business School Case 814-023, August 2013. (Revised October 2013.)
- May 2012
- Supplement
Westlake Lanes: How Can This Business Be Saved? Spreadsheet for Instructors (Brief Case)
By: Richard G. Hamermesh and Alisa Zalosh
- November 2012
- Supplement
Sugar Bowl, Spreadsheet for Students (Brief Case) (CW)
By: Richard G. Hamermesh and Alisa Zalosh
- December 2012
- Teaching Note
Gene Patents (A) (TN)
By: Richard G. Hamermesh and Matthew Preble
This is the teaching note for case Gene Patents (A). In March 2010, U.S. District Court Judge Robert Sweet overturned 30 years of legal precedent and ruled that unaltered human genes could not be patented. This case reviews patent law and how it relates to our... View Details
- July 2012 (Revised May 2024)
- Supplement
Lyric Dinner Theater (B)
By: Richard G. Hamermesh and Jim Sharpe
Supplements the (A) Case. Deborah Denenberg reflects on the results and actions taken during the 12 months following her first 6 months on the job. View Details
Keywords: Entrepreneurs; Entrepreneurial Management; Crisis; Turn; Family Business; Financial Crisis; Boards Of Directors; Operations Management; Strategy Implementation; Career Planning; Entrepreneurship; Entertainment and Recreation Industry; United States
Hamermesh, Richard G., and Jim Sharpe. "Lyric Dinner Theater (B)." Harvard Business School Supplement 813-044, July 2012. (Revised May 2024.)
- October 2010 (Revised June 2015)
- Teaching Note
MINTing Innovation at NewYork-Presbyterian (A) and (B)
By: Richard G. Hamermesh and David Kiron
Teaching Note for 810004 and 815113. View Details
- April 2009
- Teaching Note
Amylin Pharmaceuticals: Diabetes and Beyond (TN)
By: Richard G. Hamermesh and Rachel Gordon
Teaching Note for [809011]. View Details
- September 2007 (Revised October 2010)
- Case
DermaCare: Zapping Zits Directly
By: Richard G. Hamermesh and Lauren Barley
DermaCare has developed an innovative new product for the treatment of acne that they hope to sell to consumers via direct-response television. The unconventional nature of the product and its distribution has led the company to seek angel financing. The Silicon Valley... View Details
Keywords: Decision Choices and Conditions; Venture Capital; Investment; Innovation and Invention; Product; California
Hamermesh, Richard G., and Lauren Barley. "DermaCare: Zapping Zits Directly." Harvard Business School Case 808-064, September 2007. (Revised October 2010.)